Abstract
Ebola virus (EBOV) is a non-segmented negative stranded-RNA virus of the filovirus genus made of four subtypes. EBOV was first isolated in 1976 in Zaire, DRCs [1,2]. It is the most pathogenic for humans and non-human primates [3]. It has caused several outbreaks of Ebola haemorrhagic fever with the most recent occurring in West Africa [4]. EBOV disease (EVD) is characterized by onset of non-specific symptoms such as fever, asthenia, abdominal pain, myalgia, diarrhea, arthralgia, and vomiting. This usually occurs 4-7 days after exposure to infected biological fluids such as blood. Hemorrhagic signs including melaena, epistaxis, gingivorrhagia, petechiae, conjunctivitis, and spontaneous bleeding occurs in some patients, most of who die 5-9 days after the clinical onset. Case fatality ration is between 30% and 90% [5,6]. As a result of the efforts by many investigators, potential vaccines and therapeutics have been developed for EVD but till date no commercial product have been developed and are unlikely to do so in the near future due to the cost involved in developing novel products for human use and challenge of conducting clinical trials during an outbreak in developing countries who lack the necessary healthcare infrastructure. The most cost-effective and timely method to manage future outbreaks is to identify an already approved drug that might be used in combating disease caused by EBOV and other emerging pathogens [7,8]. In order to identify whether currently licensed drugs might be useful, we need to know about the pathophysiology of the disease. Analysis of biomarkers of EVD will be a useful for purpose.

This publication has 18 references indexed in Scilit: